Diego Araiza-Garaygordobil
Research Subjects
Diego Araiza-Garaygordobil has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Alejandro Barron-Martinez
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez , Juan Badiano 1, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14030
1 shared publicationAlejandro Sierra-Gonzalez de Cossio
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez , Juan Badiano 1, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14030
1 shared publicationEder Gonzalez-Macedo
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez , Juan Badiano 1, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14030
1 shared publication- Jorge Arturo Ortega-Hernandez
Programa de maestría y doctorado en ciencias médicas y odontológicas de la Salud, Universidad nacional Autónoma de México, Ciudad De México, Mexico
1 shared publication Jorge Daniel Sierra-Lara Martinez
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez , Juan Badiano 1, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14030
1 shared publicationJésus Antonio Viana-Rojas
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez , Juan Badiano 1, Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14030
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (1)
Integrated ultrasound haemodynamic profiling (VTI–VExUS) for risk stratification in acute heart failure
Aims: Clinical evaluation of congestion and perfusion in acute heart failure (AHF) has recognized limitations. Ultrasound tools such as the Venous Excess Ultrasound Score (VExUS) and the left ventricular outflow tract velocity–time integral (LVOT VTI) have gained increasing support for bedside haemodynamic profiling. We assessed the incremental prognostic value of a combined VTI–VExUS classification compared with standard clinical assessment. Methods and results: We prospectively enrolled adults admitted with AHF. Within 24 h of presentation, VExUS (congestion) and LVOT VTI (perfusion) were assessed and integrated into four ultrasound-based profiles. The primary endpoint was a 30-day composite of all-cause mortality, cardiogenic shock, mechanical ventilation, short-term ventricular assist device use, and inotropic/vasopressor therapy. Among 167 patients (mean age 58.2 ± 13.4 years; 72% male), event rates increased across VTI–VExUS profiles (11.3%, 34.6%, 32.4%, and 69.2%, P < 0.001). Discrimination was superior for the VTI–VExUS model vs. clinical assessment alone (AUC 0.74 vs. 0.58, P = 0.0016). Integrated discrimination improvement confirmed the added prognostic contribution (IDI 0.157, P = 0.004). Ultrasound profiles were independently associated with outcomes. Conclusion: VTI–VExUS ultrasound profiling provides significant incremental prognostic information beyond clinical assessment in AHF. These findings support its role as a complementary bedside tool for early risk stratification.
- 1 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (1)
Open AccessIntegrated ultrasound haemodynamic profiling (VTI–VExUS) for risk stratification in acute heart failure
Aims: Clinical evaluation of congestion and perfusion in acute heart failure (AHF) has recognized limitations. Ultrasound tools such as the Venous Excess Ultrasound Score (VExUS) and the left ventricular outflow tract velocity–time integral (LVOT VTI) have gained increasing support for bedside haemodynamic profiling. We assessed the incremental prognostic value of a combined VTI–VExUS classification compared with standard clinical assessment. Methods and results: We prospectively enrolled adults admitted with AHF. Within 24 h of presentation, VExUS (congestion) and LVOT VTI (perfusion) were assessed and integrated into four ultrasound-based profiles. The primary endpoint was a 30-day composite of all-cause mortality, cardiogenic shock, mechanical ventilation, short-term ventricular assist device use, and inotropic/vasopressor therapy. Among 167 patients (mean age 58.2 ± 13.4 years; 72% male), event rates increased across VTI–VExUS profiles (11.3%, 34.6%, 32.4%, and 69.2%, P < 0.001). Discrimination was superior for the VTI–VExUS model vs. clinical assessment alone (AUC 0.74 vs. 0.58, P = 0.0016). Integrated discrimination improvement confirmed the added prognostic contribution (IDI 0.157, P = 0.004). Ultrasound profiles were independently associated with outcomes. Conclusion: VTI–VExUS ultrasound profiling provides significant incremental prognostic information beyond clinical assessment in AHF. These findings support its role as a complementary bedside tool for early risk stratification.